FDA Grants Accelerated Approval to Ultomiris for IgA Nephropathy

The U.S. Food and Drug Administration has granted accelerated approval to Ultomiris (ravulizumab-cwvz), developed by Alexion, AstraZeneca Rare Disease, for the treatment of IgA nephropathy (IgAN) in adults at risk of rapid disease progression.

IgAN, also known as Berger's disease, is a chronic kidney condition caused by deposits of immunoglobulin A in the kidneys, leading to inflammation and progressive loss of kidney function. The disease affects an estimated 130,000 people in the United States and remains a leading cause of kidney failure among primary glomerular diseases.

Ultomiris is a long-acting C5 complement inhibitor administered intravenously every eight weeks following a loading dose. The FDA's accelerated approval was based on reduction in proteinuria, a surrogate endpoint reasonably likely to predict clinical benefit. Confirmatory trials are required to verify and describe the drug's clinical benefit.

The approval expands the existing indications for Ultomiris, which is already approved for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder.

As a complement inhibitor, Ultomiris carries a boxed warning for serious meningococcal infections. Patients must be vaccinated against meningococcal disease at least two weeks before initiating treatment or receive prophylactic antibiotics if the drug must be started sooner.

The accelerated approval pathway allows the FDA to approve drugs for serious conditions based on a surrogate or intermediate clinical endpoint while post-market confirmatory evidence is gathered, helping patients access promising therapies earlier in the development process.